English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 May 2023, 07:00 HKT/SGT
Share:
    

Source: CellOxess Biotechnology
Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

CLERMONT-FERRAND, FRANCE, May 19, 2023 - (ACN Newswire) - According to a recent study by Universite Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.

Fertilix(R) logo

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF. These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers. While researchers found no appreciable effect on general semen parameters typically examined in fertility clinics such as sperm counts and motility, significant oxidation and decompaction of DNA structure in sperm cells were observed. This is concerning because damage to paternal genetic material can expose the female partner to higher risk of pregnancy loss and potentially impact the health of the offspring. Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.

Given that microplastics are found everywhere in our surroundings, these findings underscore the importance of greater public awareness and the urgency for the plastic industry to replace such substances with biodegradable or natural alternatives. Furthermore, fertility experts counseling couples ahead of natural or assisted conception should advocate for preconceptual supplementation and possible lifestyle modifications that may mitigate the impact of environmental pollutants.

This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here. https://www.mdpi.com/2076-3921/12/5/1046 CellOxess Biotechnology, the designer and manufacturer of Fertilix(R) formulations, will present the full results of this study at the European Society of Human Reproduction and Embryology (ESHRE) annual meeting this June in Copenhagen, Denmark.

Contact Information
Frances Gallagher, MPH
Marketing & Communications Coordinator
contact@celloxess.com

Topic: Press release summary
Source: CellOxess Biotechnology

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
CITIC Telecom CPC's 'AI+ Coud Network Security' Innovation Continues to Attain Recognition for Unmatched Capabilities  
July 13, 2024 00:05 HKT/SGT
MooFest 2024 by Moomoo Singapore and AlphaInvest Receives Massive Turnout  
July 12, 2024 19:30 HKT/SGT
TOYOTA GAZOO Racing faces a new challenge with full strength  
Friday, July 12, 2024 6:15:00 PM
MHI Selected for Inclusion in Two ESG Investment Indices: FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index  
Friday, July 12, 2024 3:13:00 PM
TGR Announces Upgraded GR86 and Limited Special-edition Model  
Friday, July 12, 2024 1:48:00 PM
Asia-Pacific youth and Habitat for Humanity join hands to implement solutions for decent housing  
July 12, 2024 13:06 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel  
Friday, July 12, 2024 11:56:00 AM
KSL Capital Partners & Soneva Resorts: A Cautionary Tale of Due Diligence  
July 12, 2024 08:34 HKT/SGT
Q2 Metals Updates Private Placement  
July 12, 2024 08:00 HKT/SGT
Fonos Sees Monthly Active Users Increase to 6X with CleverTap's Personalized Engagement  
July 11, 2024 15:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575